Keytruda is a new immune-oncology drug to treat advanced melanoma released recently by Merck Group at a cost of over $10,000 per month, per patient. Yet again we have a new cancer treatment that is prohibitively expensive released onto the market. Yet again we have clamouring for the government via Pharmac to shell out the extortionate amount of money required to procure the drug.
Of course the government should fund the drug, as it should fund any treatment proven to be effective in treating illness or disease. However the money will have to come out of an already stretched health budget or increased taxes. And it is totally unnecessary. The drug, like most new and effective treatments, is grossly overpriced in relation to the cost of production. Continue reading